External broker reports(aggregated public sources), Canaccord Genuity

Canaccord Genuity

Canaccord Genuity Group Inc. is a leading independent investment bank with operations in North America, UK & Europe and Asia-Pacific. Canaccord Genuity Group Inc. is a leading independent, full-service financial services firm. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<div><ul><li>This week, there were two international licensing deals in the RNA editing space by big pharma giant Novo Nordisk.</li><li>While details on specific terms were not released, we view activity in the sector as good for PYC and biotech in general, noting big pharma willingness to take on earlier stage risk and increased attention to the RNA space as a preferred sub-segment of gene editing.</li><li>Recall, recent clinical updates from its most advanced program, RP11 (blinding eye disease) demonstrated VP-001 had a notable (albeit early) positive effect on visual sensitivity, which was a key focus on the conference call.</li></ul></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

This week, there were two international licensing deals in the RNA editing space by big pharma giant Novo Nordisk.While details on specific terms were not released, we view activity in the sector as good for PYC and biotech in general, noting big pharma willingness to take on earlier stage risk and increased attention to the RNA space as a preferred sub-segment of gene editing.Recall, recent clinical updates from its most advanced program, RP11 (blinding eye disease) demonstrated VP-001 had a notable (albeit early) positive effect on visual sensitivity, which was a key focus on the conference call.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

PYC Therapeutics Limited - The RNA Space Is Heating Up